


REMARKS/ARGUMENTS


After entry of the amendment, Claims 1-28 remain in this application. Claims 1, 10, 13, 16, 18 and 19 have been amended. Claims 15-28 have been withdrawn.

The Examiner has restricted prosecution of this application to one of forty groups of claims. Applicants elect Group I (Claims 1-11) without traverse. The pending claims have been amended to recite the compound of Formula I wherein X is H, cyano, halogen, haloalkyl, NO, NO₂, NO₃, phosphonates, PR¹⁵R¹⁶R¹⁷, NH₂, NR¹⁵R¹⁶, OH, OR¹⁵, SR¹⁵, SCN, N₃, OC(O)R¹⁵, C(O)₂R¹⁵, OC(O)NR¹⁵R¹⁶, C(O)₂NR¹⁵R¹⁶, C(O)NR¹⁵R¹⁶, P(O)₂OR¹⁵, S(O)₂R¹⁵, alkyl, alkenyl, alkynyl, aryl, aralkyl, alkaryl, heteroalkyl, heterocycle, heteroaryl, or alkylheteroaryl and T is a therapeutic agent. Applicants also elect Group XI (Claims 12-14), the composition claims that correlate with the elected group.

The Examiner has also required an election of species. Applicants elect the species of the compound of Formula I wherein X is H, and more specifically the compound described in Example 19:



Wherein X is H and R is:




Applicants note that the Examiner has stated that if the Applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims of Group XXI (Claims 15-28) that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04.

The Commissioner is authorized to charge any fees or credit any overpayment to Deposit Account No. 11-0980.

Respectfully submitted,

KING & SPALDING LLP

By: 
Madeline I. Johnston, Ph.D., Esq.
Reg. No. 36,174

191 Peachtree Street, 45th Floor
Atlanta, Georgia 30303-1763
Tel.: (404) 572-3541